Abstract Tenascin-X (TNX) is a large 450 kDa extracellular matrix protein expressed in a variety of tissues including skin, joints and blood vessels. DeWciency of TNX causes a recessive form of Ehlers-Danlos syndrome characterized by joint hypermobility, skin fragility and hyperextensible skin. Skin of TNX deWcient patients shows abnormal elastic Wbers and reduced collagen deposition. The mechanism by which TNX deWciency leads to connective tissue alterations is unknown. Here we report that C-terminal domains of human TNX bind to major dermal Wbrillar collagens and tropoelastin. We have mapped these interactions to the Wbronectin type III repeat 29 (FNIII29) and the C-terminal Wbrinogen domain (FbgX) of TNX. In addition we found that FNIII29 of TNX accelerates collagen Wbrillogenesis in vitro. We hypothesize that TNX contributes to matrix stability and is possibly involved in collagen Wbril formation.
Introduction
Tenascin-X is a large extracellular matrix glycoprotein composed of EGF like-repeats, Wbronectin type III (FNIII) repeats and a C-terminal Wbrinogen domain (FbgX) [1, 5, 6, 12] . TNX abnormalities are associated with several pathological conditions [2, 22, 27] . Complete deWciency of TNX in humans leads to a recessive form of Ehlers Danlos syndrome (EDS) and TNX haploinsuYciency is a cause of hypermobility type EDS. The skin of TNX deWcient patients is markedly lax with poor recoil properties and shows easy bruising [2, 14, 20, 22, 27] . We have previously shown TNX to be present in the entire dermis of healthy individuals. During development in mice TNX colocalises with the major Wbrillar collagens and elastic Wbers in the dermis [3, 22] . Adult TNX deWcient patients show abnormal elastic Wbers and reduced collagen deposition in skin [28] . The mechanism by which TNX deWciency leads to alterations in the extracellular matrix (ECM) is unknown. Mapping of TNX domains that interact with components of the elastic Wbers or collagen is therefore an important step to deWne the role of TNX in connective tissue biology of human skin.
It has previously been shown that bovine and murine TNX bind to heparin [13, 16] . In bovine TNX a conformational heparin-binding site has been identiWed involving FNIII repeats 10 and 11 in the N-terminal half of the molecule. This heparin-binding site is also involved in the binding of TNX to decorin, and it was proposed that TNX interacts with collagen through decorin [4] . Minamitani et al. showed that the short isoform of murine TNX binds directly to collagen type I, probably through interaction with one of the Wbronectin type III repeats. This short isoform was found to promote collagen Wbrillogenesis in vitro [18] .
The aim of our study was to investigate the molecular mechanisms of the observed phenotype in TNX-deWcient EDS patients. We therefore analyzed interactions of human TNX with elastic Wber components and with the major Wbrillar collagens in the dermis (collagen type I, III and V). We found that the C-terminus of TNX harbors potential interaction sites with collagens type I, III and V and tropoelastin (TE), which are constituents of the anatomical structures that are abnormal in the dermis of these patients.
Materials and methods

Expression and puriWcation of recombinant TNX fragments
The TNX fragments were ampliWed by PCR with the primers listed in Table 1 using a previously described 2.7 kb human TNX cDNA [19] as a template. PCR products were ligated into the pCR2.1TOPO vector (Invitrogen, Breda, NL) according to the manufacturer's instructions for easy digestion with restriction enzymes. The pCR2.1 TOPO vectors with inserts were digested with EcoRI and SalI and cloned into the EcoRI/SalI site of the pMal-c2X plasmid (Westburg B.V., Leusden, NL). Subsequently the DNA sequences coding for FNIII29 and FNIII29-30 of TNX were cloned into the EcoRI/SalI site of the pGex-4T1 plasmid (GE Healthcare Life Sciences, Diegem, BE). The sequence of the TNX domains was veriWed by dideoxy sequencing with a 3730 DNA analyzer (Applied Biosystems, Nieuwekerk a/d IJssel, NL). TNX fragments were obtained as maltose binding protein (MBP) fusion proteins using E.coli TOP10F' cells (Invitrogen) according to the manufacturer's instructions. MBP fusion proteins were isolated on amylose resin columns and analyzed for purity with SDS-PAGE. MBP fusion proteins were incubated with factor Xa (Westburg B.V.) in an attempt to remove the MBP tag from the fusion protein according to the manufacturer's instructions. FNIII29-30 without tag was obtained by proteolytic cleavage of FNIII29-30 from a glutathione-S-transferase (GST) fusion protein bound to a glutathionesepharose4B column (GE Healthcare Life Sciences) according to the manufacturer's instructions.
Proteins and antibodies
A 100 kDa C-terminal recombinant TNX protein, containing six FNIII repeats and a Wbrinogen domain, encoded by a 2.7 kb TNX sequence has previously been described by Tee et al. [19, 23] [10] . Human recombinant Wbrillin domains, Tb2-cbEGF11, Tb3-cbFGF11, cbEGF11-14, cbEGF22-23, cbEGF28-30, tb6-cbEGF32, cbEGF32-36, tb7-cbEGF37, were generously donated by Dr. P.A. Handford (Oxford University, Oxford, UK) [7, 9, 11, 17, 24, 25] . BSA and gelatin were obtained from Sigma-Aldrich (Sigma-Aldrich Chemie B.V., Zwijndrecht, NL). BSA was used as a negative control. MBP was obtained from New England Biolabs (Westburg B.V.) and used as a negative control.
We used monoclonal antibodies speciWc for MBP (Westburg B.V) and a previously described guinea piganti-TNX serum [22] for detection of untagged 100 kDa TNX and MBP-TNX-domains in our solidphase assays. Pre-immunization serum was used as a 
negative control [22] FNIII29-30 of TNX was detected with a new aYnity puriWed polyclonal rabbit antiserum, raised against a MBP-FNIII29-30 antigen.
Collagen Wbrillogenesis assays Native bovine type I collagen (BD Biosciences, Alphen aan den Rijn, NL) 2.9 mg/ml in 0.012 N HCl, as provided by the manufacturer, was dissolved in PBS. MBP, BSA, MBP-FNIII29, FNIII29-30 and 100 kDa TNX were added to samples in cuvettes after which the Wnal volume was adjusted to 1 ml of 0.4 mg/ml collagen type I with PBS and incubated at 30°C. Turbidity change was measured by monitoring the change in absorbance at 400 nm in a UV-160A Shimadzu spectrophotometer (Shimadzu Benelux, Den Bosch, NL) at Wxed intervals. Data points represent the mean of triplicate measurements.
Binding assays
Ninety-six well microtiter plates (Greiner Bio-One B.V., Alphen aan den Rijn, NL) were coated overnight at 4°C with ECM components diluted in PBS. All further incubation steps were performed at 37°C. After each incubation step wells were washed with PBS containing 0.05% Tween-20 (T-PBS). Wells were saturated with 1% BSA in T-PBS for 2 h and then incubated with recombinant TNX domains for 1 h. This was followed by incubation with antibodies against the recombinant TNX fragments for 1 h. Thereafter, wells were incubated with biotinylated anti guinea pig (Vector Laboratories Inc., Burlingame, CA, USA), biotinylated anti rabbit (Vector Laboratories Inc.) or anti mouse IgG (vectastain kit, Brunschwig Chemie, Amsterdam, NL) for 1 h followed by a 45 min incubation with an avidin-biotin-horse radish peroxidase mixture (vectastain kit, Brunschwig Chemie).
Bound peroxidase was detected with o-phenylenediamine dihydrochlorid (Perbio Science Nederland B.V., Etten-Leur, NL) and the absorbance read at 490 nm. All antibodies and TNX proteins were diluted in T-PBS containing 0.1% BSA. PBS was substituted by tris buVered saline (TBS) + 5 mM Ca 2 Cl 2 in solid phase assays in which binding of TNX to Wbrillin-1 domains was investigated for proper folding/stability of the Wbrillin-1 domains [7, 21] . Assays were performed at least twice. BSA, MBP and pre immunization guinea pig serum were used as negative controls or baseline correction.
As an alternative to the binding assay in ELISA format we investigated binding of MBP-FNIII29 to collagen Wbrils generated during the Wbrillogenesis assay.
BrieXy, various concentrations of MBP-FNIII29 were incubated overnight at 30°C in the presence of 0.1% BSA or collagen type I (0.4 mg/ml) + 0.1% BSA. Thereafter, the insoluble collagen Wbrils were pelleted by centrifugation. The concentration of MBP-FNIII29 in the supernatant was determined using an assay similar to a previous described one [22] in which, instead of guinea pig anti TNX antiserum, fusion protein was detected with monoclonal antibodies speciWc for MBP (Westburg B.V.).
SDS-PAGE analysis
Proteins were loaded onto 12% Bis-Tris gels (Invitrogen) gel electrophoresis was carried out using the NuPAGE system according to the manufacturer's instructions (Invitrogen) . To analyze protein purity gels were stained using coomassie brilliant blue R250 (Brunschwig).
Results
Binding of C-terminal 100 kDa TNX to extracellular matrix components
We postulated that TNX might interact with components of elastic Wbers or collagens directly because of the disturbed properties of collagens and elastic Wbers in TNX deWcient patients. As a Wrst approach to identify extracellular ligands of TNX, we performed solid phase assays to test binding of a recombinant C-terminal 100 kDa TNX fragment [19, 23] (soluble phase) to ECM molecules (immobilized substrates). Figure 1 a shows that TNX binds dose dependently to human collagens type I, III and V. Binding to BSA, which served as a negative control, was absent. Figure 1b compares the relative values of recombinant C-terminal 100 kDa TNX binding to human Wbrillar collagens, at the highest concentration of fusion protein compared to the control values of BSA. Figure 2 a shows the interaction of TNX with bovine collagen type I, bovine tropoelastin and denatured collagen type I (gelatin). TNX did not bind to denatured bovine collagen (gelatin). Figure 2b compares the relative values of recombinant C-terminal 100 kDa TNX binding to bovine tropoelastin, collagen type I and gelatin, at the highest concentration of fusion protein compared to the control values of BSA. Half maximal saturation, a measure for the aYnity of the interaction, was reached at a concentration of soluble 100 kDa TNX of 1.8 £ 10
¡8 M for human collagen type I and 4.0 £ 10 ¡8 M for bovine collagen type I. Half maximal saturation was reached at 1.1 £ 10 ¡8 M for human collagen type III, 0.8 £ 10 ¡8 M for human collagen type V and 1.8 £ 10
¡8 M for tropoelastin. We did not observe binding to several domains of the elastic Wber protein Wbrillin-1 (data not shown).
Binding of speciWc C-terminal TNX fragments to extracellular matrix components To identify the sequences in TNX responsible for binding to the ECM components we subcloned and expressed a number of fragments from the C-terminal 100 kDa TNX protein. Figure 3 gives a schematic overview of these fragments, and shows the purity of the fusion proteins used in this study. The domains studied here were produced as MBP-fusion proteins and included overlapping tandems of FNIII repeats and the FbgX domain.
All recombinant proteins containing the FNIII29 repeat showed dose dependent binding to collagen type I, III and V. As an example the binding curves for collagen type V are shown in Fig. 4a . Only FNIII29, FNIII28-29 and FNIII29-30 showed strong binding, whereas no binding was observed for repeats FNIII27- Figure 5a depicts binding of TNX fragments to recombinant bTE. All fusion proteins containing FNIII29 were found to bind to TE, but in addition we found interaction with the FbgX domain, which was not the case for collagens. Recombinant MBP shows some non-speciWc binding to bTE but this is clearly less than FNIII29 and FbgX containing recombinant proteins. This non-speciWc binding was also observed for BSA, FNIII27-28 and FNIII30-31. The lines from these proteins coincide with the line of the MBP control, therefore they were omitted from Fig. 5a for reasons of clarity. Figure 5b compares the relative values of FNIII29, FNIII27-28 and FbgX binding to recombinant TE, at the highest concentration of fusion protein compared to the control values of MBP.
We used TNX domains fused to MBP because this allows simple high yield puriWcation and-importantly-it allows comparison and easy detection of bound fusion proteins by a single anti-MBP antibody. MBP alone was used as a control throughout the studies described above. In order to check if MBP fused to TNX domains would cause artiWcial binding of fusion proteins to ECM molecules we decided to test binding of a recombinant TNX fragment without MBP. Unfortunately, it was not possible to produce FNIII29 as a single repeat protein without fusion protein tag in either the pMal protein fusion or GST gene fusion system. We therefore produced a recombinant FNIII29-30 repeat devoid of fusion tag and raised an antibody against FNIII29-30. Figure 6 shows that pure recombinant FNIII29-30 essentially has the same binding properties towards Wbrillar collagens and TE as the MBPfusion protein, indicating that the interaction site resides in the TNX moiety (FNIII29) of the fusion proteins.
Stimulation of Wbrillogenesis by FNIII29
To extend the observed binding properties of TNX FNIII repeats at the functional level, we investigated whether the collagen binding FNIII29 repeat of human TNX could modulate collagen Wbrillogenesis. Using a turbidity assay (see Fig. 7a ) we found an increase in the rate of Wbril formation and a shortening of the lag phase in the presence of the FNIII29 repeat of TNX compared to the control proteins (BSA (not shown) and MBP) The Wbrillogenesis rate in the lateral growth phase, characterized by Wbril-and aggregate formation [8, 26] , was signiWcantly increased (P < 0.001) when 48 g/ml MBP-FNIII29 was added. At a concentration of 24 g/ml, MBP-FNIII29 does not signiWcantly inXuence the lateral growth phase, although it shortens the lag phase, characterized by linear growth of microWbrils and early Wbril formation [8, 26] , compared to controls. After 24 h all samples reached a similar maximal OD (data not shown). FNIII29-30 had only a minimal eVect on collagen Wbrillogenesis compared to MBP-FNIII29 and C-terminal 100 kDa TNX showed no signiWcant eVect on either the lag-or lateral growth phase of collagen Wbrillogenesis (data not shown).
The Wbrillogenesis assay also provided us with an alternative method to investigate binding of TNX fragments to ECM molecules. To investigate the binding of MBP-FNIII29 to the collagen Wbrils formed during the assay, we measured the amount of MBP-FNIII29 that 
Discussion
We established a number of novel in vitro binding properties of human TNX that reside in the 100 kDa C-terminal portion. The binding properties of this fragment could be largely ascribed to the FbgX domain (tropoelastin binding) and the FNIII29 repeat, which was found to bind strongly to tropoelastin and collagen types I, III and V. Previous studies by others, using bovine and murine TNX have found binding to decorin [4] and collagen type I [18] . In the latter study, deletion of the EGF-like repeats or the FbgX domain did not abolish collagen binding, suggesting that binding of murine TNX resides somewhere in the FNIII repeats.
The binding to elastin was particularly interesting, as abnormal elastic Wber morphology is a characteristic feature of EDS patients with a complete TNX deWciency. We found binding of tropoelastin both to FNIII29 and FbgX. In contrast to FNIII29 the FbgX domain only binds to TE and not to other tested ECM proteins. The functional signiWcance of this Wnding requires further investigation, but this interaction could be involved both in maturation or stability of the elastic Wber.
Dermal collagen deposition is reduced in TNX deWcient patients, and their skin and other connective tissues is fragile as witnessed by easy bruising [22, 28] . The skin strength in TNX deWcient mice is markedly reduced, although the signiWcance and magnitude of the reduction of collagen deposition is debated [3, 15, 18] . In mice, the variation in collagen Wbril diameter appears to be increased [15, 18] . Speculatively, the assembly or stability of collagen Wbrils could be disturbed in TNX deWcient patients. We found that the FNIII29 domain of human TNX is able to accelerate the collagen Wbril formation in vitro. In contrast, however, we failed to detect a signiWcant eVect of the 100 kDa TNX fragment on Wbrillogenesis. This might possibly be due to conformational changes caused by folding of the 100 kDa TNX in solution that precludes an eVect on Wbrillogenesis, although the 100 kDa fragment binds to collagen type I. Alternatively, the observed eVect of the TNX FNIII29 repeat on Wbrillogenesis could be artiWcial, because it is not known whether it is accessible to collagen in the native 450 kDa protein. Minamitani et al. found that a short isoform of murine TNX could accelerate collagen Wbrillogenesis in an assay similar to the one we used [18] . Interestingly, they found that deletion of the EGF repeats or Wbrinogen domain did not have an eVect on binding of TNX to collagen although collagen Wbrillogenesis kinetics were aVected by deletion of these domains. Possibly conformational changes could account for this aVect. Furthermore, we observed binding of the TNX FNIII29 repeat to the insoluble collagen Wbrils formed during in vitro Wbrillogenesis. This is in agreement with the observed binding properties of this domain in our solid phase assay in ELISA format. For Wbrillar collagens type III and V we observed that preincubation of TNX FNIII29 with these collagens reduced the measured amount of TNX compared to controls in a previously described TNX ELISA [22] (data not shown). These Wndings are in accordance with the results from our solid phase binding assays. Clearly, the functional consequences of the interaction of TNX domains require further investigation. Ideally, the complete human 450 kDa [1] or adrenal speciWc 74 kDa [23] TNX form with correct glycosylation should be produced or puriWed, to provide deWnitive answers with respect to molecular interactions and eVects on Wbrillogenesis. On the other hand, the molecular diversity of TNX is far bigger than anticipated. We have found that various fragments of TNX, ranging from 70 to 450 kDa are present in human serum (unpublished results). Whether these represent alternative splice forms or posttranslationally processed fragments is unknown. All of these TNX forms contain the FNIII29 repeat and it is possible that these shorter forms adopt a conformation in which FNIII29 is exposed to exert binding to ECM molecules and causes functional eVects.
In conclusion, our study shows that domains of TNX directly interact with a number of ECM molecules that form a major part of the aVected structures in the dermis of TNX deWcient patients. Our data could serve as a starting point to investigate the function of individual domains in the context of the physiological TNX Fig. 6 Binding of FNIII29-30 to ECM proteins. Recombinant FNIII29-30 (without fusion tag) binds to collagen types I, III and V and to TE essentially in the same manner as the MBP fusion proteins containing FNIII29. BSA is used as a control for background staining (7.5 g/ml)
Fig. 7 TNX FNIII29 aVects collagen Wbrillogenesis. a TNX FNIII29 has a dose dependent eVect on the Wbrillogenesis rate of bovine collagen type I in a turbidimetric assay. At a concentration of 48 g/ml MBP-FNIII29 the Wbrillogenesis rate in the lateral growth phase is signiWcantly increased. At a concentration of 24 g/ml MBP-FNIII29 does not signiWcantly inXuence the lateral growth phase, although at both 24 and 48 g/ml the lag phase is shortened. MBP and BSA served as a negative control. The curves of BSA and 4.8 g/ml MBP-FNIII29 overlapped with the MBP curve and have been omitted for reasons of clarity. b Comparison of TNX FNIII29 levels in the supernatant of pelleted insoluble collagen Wbrils compared to controls. DiVerences of TNX FNIII29 concentration in the supernatant reXect the amount of TNX FNIII29 bound to the pelleted insoluble collagen Wbrils molecules, like the 450 kDa tissue form or the various serum forms. Further investigation of the role of TNX in extracellular matrix assembly and stability will increase our knowledge of connective tissue biology and will oVer a molecular explanation for the phenotype of TNX deWcient patients.
